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Abstract: Medical therapy is the first treatment choice for most patients with glaucoma; 
however, in a relevant proportion of patients, intraocular pressure (IOP) reduction is achieved 
with multi-therapy and/or high therapeutic doses. Conventional surgery is the standard 
alternative to medical therapy when this is not effective or not tolerated. Recently, selective 
laser trabeculoplasty (SLT) has been advocated as first-line therapy, and “minimally invasive 
glaucoma surgery” (MIGS) has been developed as safer and less traumatic surgical inter-
vention for patients with glaucoma. Schlemm’s canal surgery has emerged as one of the 
approaches with the most favorable risk-benefit profile for glaucoma patients in need of 
cataract surgery. However, despite the promising results, use of MIGS in Italy has been 
extremely low. We aimed to investigate the reasons of the lower-than-expected use of 
Schlemm’s canal-based MIGS devices in Italy, share our perspective on their potential 
place in therapy, and give practical suggestions to improve the management of glaucoma 
patients. 
Keywords: minimally invasive surgery, glaucoma, IOP reduction, trabecular bypass, 
cataract surgery
Introduction
Glaucoma is an optic neuropathy characterized by the progressive degeneration of 
the retinal ganglion cells, with consequent visual field loss, which slowly leads to 
blindness.1
Glaucoma represents one of the major health problems, being the second cause 
of blindness worldwide, and its prevalence is still growing very quickly (about 
80 million people affected).2 In Italy, recent estimates show that about 550 thousand 
subjects have a confirmed diagnosis of glaucoma; this corresponds to about 2% 
prevalence in population aged ≥40 years.3 Furthermore, glaucoma is a burdensome 
condition that can dramatically affect individuals’ quality of life (QoL): irreversible 
visual impairment and potential blindness caused by glaucoma have an extremely 
negative impact on patients’ physical and mental health.4
In primary open-angle glaucoma (POAG) patients, outflow obstruction at the level 
of the trabecular meshwork and Schlemm’s canal is likely the main cause of high 
intraocular pressure (IOP). Many patients with POAG also have a concomitant catar-
act: this association is reported in the published literature, and it was demonstrated that 
patients with glaucoma are at higher risk of developing cataract.5–8 Both cataract and 
glaucoma are age-related diseases, and they are likely to present concomitantly in 
elderly people.9–18 Several studies have demonstrated that cataract extraction alone in 
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glaucoma patients can reduce IOP.19–22 However, there is 
still an important unmet need in these patients.23 Optimal 
target IOP will be obtained with medical treatment, glau-
coma surgery, or both. In the last decade, minimally invasive 
glaucoma surgery (MIGS) has been developed as safer and 
less traumatic surgical intervention for patients with glau-
coma versus incisional surgery.24 In Italy, few devices are 
currently marketed (GATT, ABiC, Kahook, iStent inject). 
iStent inject® (Glaukos Corporation, San Clemente, CA, US, 
hereafter “second-generation trabecular micro-bypass stent” 
- TBS) has emerged as a safe option among MIGS device, as 
it does not require trabecular meshwork removal.25–28
In Italy, the adoption rate of these emerging treatments 
(selective laser trabeculoplasty – SLT, MIGS) is still low 
compared with other European countries and the US. This 
can be explained by two main reasons: i) only a few specia-
lized centers perform SLT and MIGS regularly, whereas 
most hospitals stick to the traditional treatment approach in 
uncontrolled, advanced, or severe cases; ii) treatment suc-
cess rate with the first methods introduced in medical prac-
tice (Trabectome® and iStent®) has been modest.
Despite the limited offer of new therapeutic options, the 
treatment demand in Italy is high and constantly increasing. 
In fact, about 550,000 patients undergo cataract extraction 
every year. Assuming that 5%-10% of these patients have 
(or will develop) glaucoma,29 there would be a maximum of 
about 50,000 patients/year in need of a combined interven-
tion of cataract extraction and glaucoma management.
In this paper we aim to: i) analyze the reasons of the 
lower-than-expected use of glaucoma emerging treat-
ments; ii) give practical suggestions to improve manage-
ment of glaucoma patients and address the current unmet 
needs in this area; iii) share our perspective on the poten-
tial place in therapy of MIGS, and second-generation TBS 
specifically, in glaucoma.
Key-Decision Treatment Criteria in 
Glaucoma
The ultimate goal of glaucoma treatment is to minimize the 
optic nerve damage and to safeguard the residual visual field/ 
capacity of patients. This can be achieved through sustained 
IOP reduction.30,31 The European Glaucoma Society (ESG) 
Guidelines (Year 201732) state that “there is not enough 
evidence to support any particular algorithm to set the target 
IOP”. However, in clinical practice, identification of absolute 
IOP target reduction (<21mmHg, <18mmHg, etc.) and rela-
tive (vs baseline) IOP target reduction (≥20%, ≥30%, etc.) 
should depend on a multifactorial assessment of the patient. 
Figure 1 illustrates the main criteria driving the decision on 
IOP target level:
Rate of Progression
Optimal management of glaucoma implies that patients 
would be monitored and staged regularly with both func-
tional tests (visual field; staging classification based on 
Hodapp, Parish and Anderson; H-P-A) and structural 
Figure 1 Main criteria for setting the target IOP°. °The above factors need to be considered as a whole in deciding the individual target pressure required. *Consider central 
corneal thickness.  
Abbreviation: IOP, intraocular pressure.
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tests.33 This approach would help ophthalmologists to 
accurately assess the disease progression rate, and to 
select the more appropriate treatment approach, with fil-
tering surgery being preferred over medical therapy and/ 
or minimally invasive approaches for highly progressing 
patients.
Glaucoma Damage
The more glaucoma is advanced, the higher is the need to 
target low IOP.32,34,35 Therefore, patients with significant 
glaucomatous damage require a more resolutive interven-
tion to ensure that IOP would be significantly reduced and 
that residual visual field maintained.
Age/Life Expectancy
Likely, patients with early-onset are likely to manifest with 
glaucoma.34 In these cases, early intervention with effec-
tive, surgical treatment, is recommended to preserve visual 
functionality and avoid early visual impairment.36,37 
Instead, for older patients, more conservative approach 
based on treatments with a minor alteration of the eye 
anatomy is preferred.
Comorbidities and Risk Factors
The presence of concomitant diseases increases with 
patients’ age. In older patients with relevant comorbid-
ities, the traditional surgical approach might be contra-
indicated or have a questionable risk–benefit ratio. In 
the latter case, the decision to perform surgery must be 
evaluated carefully, and other alternatives with a higher 
level of safety should be considered/preferred. As men-
tioned earlier, patients with mild-to-moderate glaucoma 
and cataract undergoing phacoemulsification and artifi-
cial lens implantation might have a limited benefit in 
time.38,39
Untreated IOP
Unless patients have early-onset and/or rapidly evolving 
disease, the common glaucoma treatment approach is to 
start with less invasive options and then switch to more 
invasive treatments, in case the disease is not adequately 
controlled. However, an interesting debate has arisen on 
how to rank therapeutic interventions by the level of 
invasiveness, ie, level of anatomical modification of the 
eye, induced by the treatment.
Glaucoma Treatment Landscape: 
General Overview
Established Treatments
For many years, the traditional paradigm of glaucoma treat-
ment has been exclusively based on medical therapy (the 
recommended option to treat patients with initial mild-to- 
moderate disease) and on filtering surgery to manage patients 
with more advanced and/or rapidly progressing forms.
Medical Therapy
Several randomized clinical trials and observational studies 
have confirmed that antiglaucoma drugs are effective in redu-
cing IOP at different stages of the disease.31,40-42 Different 
classes of drugs (alpha2-agonists, beta-blockers, topical car-
bonic anhydrase inhibitors, cholinergics, prostaglandins/pros-
tamides, Rho kinase inhibitors), can be used, either as 
monotherapy or in combination. The choice of optimal med-
ical therapy depends on multiple factors, such as clinical 
presentation of the patient, risk–benefit ratio of the treatment, 
likelihood of adherence, impact on patient QoL. Overall, 
treatment guidelines recommend administration of the mini-
mal amount of medication (try to avoid high dosage and 
multitherapy) to achieve the desired IOP therapeutic 
goal.32,43 Though medical therapy is a key-asset for ophthal-
mologists and their patients, certain treatment issues have 
been significantly debated among ophthalmologists. For 
instance, the occurrence of side effects (eye inflammation, 
itching, sight disturbances) causes poor adherence, thus redu-
cing therapeutic effectiveness. Additionally, administration of 
eye drops is not easy for patients and their caregivers; admin-
istration is often performed suboptimally, and/or patients for-
get to self-administer the drug. Several clinical studies have 
shown that persistence to glaucoma medical therapy (intended 
as the length of time during which the patient is taking the 
medication as prescribed) is short: many patients tend to 
interrupt treatment early.44,45 In addition, topical treatments 
can cause injury to the conjunctiva and as a result can cause 
reduction in the effectiveness of surgery.44,45
Finally, IOP control is often achieved with multiple 
topical glaucoma medications and high therapeutic doses. 
Consequently, the achievement of target IOP is obtained at 
the cost of damaging the cornea, as prolonged use of high- 
dose medical therapy can modify the eye anatomy.46–48
Glaucoma Filtering Surgery
Conventional surgery has been the standard alternative to 
medical therapy and the mainstay of treatment for 
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glaucoma patients: i) who have failed to have IOP con-
trolled with less invasive options; ii) who are contraindi-
cated to medical therapy; iii) for whom a lower target IOP 
must be achieved; iv) who have early-onset and/or rapidly 
progressing glaucoma. The primary goal of surgery is to 
reduce IOP and medication.32,43
Conventionally, incisional surgery is classified into two 
main categories: i) anterior filtering surgery, and ii) poster-
ior filtering surgery. Trabeculectomy is by far the most 
common of (penetrating) anterior filtering technique and is 
extensively used in OAG. Robust clinical evidence has 
shown that trabeculectomy is an effective treatment to 
achieve sustained IOP reduction without medical 
therapy.49–51 However, as for any surgical approach, safety 
remains a concern. Despite technological advancements, 
there is a periprocedural and postprocedural “inelimin-
able” risk of adverse events, such as hemorrhage, 
endophthalmitis (filtering post-procedure incidence ranges 
from 0.12% to 8.33%), ocular infections, hypotony, visual 
loss (8.3% of patients showed loss of visual acuity after 
the first 3 months post-surgery), cataract development (the 
risk of requiring cataract surgery is reported as ranging 
between 20% and 52% up to 7 years postoperatively).52,53 
Also, the impact on QoL is non-negligible, with patients 
reporting post-surgical pain, and overall reluctance or fear 
to undergo surgery.4,54 Other non-penetrating techniques 
have been used as alternatives to trabeculectomy to poten-
tially reduce the burden of complications, but with less 
satisfactory IOP outcomes and other technical issues.55–58
Finally, posterior filtering surgery is used as a rescue 
option for those refractory patients who are still uncon-
trolled despite anterior filtering surgery ± medical therapy, 
or in patients in whom anterior filtration is not possible or 
has a high risk of failure.59–62 The use of tube shunts has 
grown in recent years. However, despite clinical evidence 
has shown favorable outcomes associated with posterior 
filtering surgery, uncertainty remains on the risks of surgi-
cal complications.63,64 Many glaucoma specialists still 
consider posterior filtration as a second option.65,66
Emerging Treatments
Selective Laser Trabeculoplasty (SLT)
The initial attempts to use laser therapy to reduce IOP in 
glaucoma patients initiated almost 50 years ago. However, 
SLT, the most common and perhaps the most advanced 
among laser therapy techniques, has emerged as an option 
for glaucoma patients as of the early 2000s.67 The efficacy 
and safety of SLT have been evaluated in several clinical 
trials and observational studies.68–78 With respect to SLT, 
the LiGHT study is an interesting observer-masked, ran-
domized controlled trial that enrolled treatment-naïve 
patients with open angle glaucoma or ocular hypertension 
and no ocular comorbidities.79 This is the first trial of 
a directly comparing SLT and intraocular pressure- 
lowering drops in terms of health-related quality of life, 
clinical, and cost-effectiveness outcomes in a pragmatic 
hospital setting, guided by a robust treatment escalation 
protocol to capture realistic clinical management while 
minimizing risk of bias. In this study, patients were allo-
cated to initial SLT or to eye drop. At 36 months, 74.2% 
(95% CI 69.3–78.6) of patients in the selective laser tra-
beculoplasty group required no drops to maintain intrao-
cular pressure at target.79 Overall, evidence shows that 
SLT reduces IOP levels and IOP fluctuation in patients 
with POAG and ocular hypertension (OHT).74,79,80 
However, the effect of trabeculoplasty may be temporary. 
Nevertheless, SLT can be repeated, as it causes minimal 
damage to the trabecular meshwork.
With the current data, it is hard to compare the efficacy of 
SLT vs other glaucoma therapies. Recent meta-analyses of 
SLT vs medical therapy81,82 suggested that SLT would be as 
effective as medication. However, some methodological lim-
itations of these analyses, combined with the lack of long- 
term efficacy data, suggest caution to avoid drawing erro-
neous conclusions, as evidence vs surgical therapy is still 
anecdotical. An analysis conducted in 2017 by Fea et al,83 
which compared SLT vs MIGS, concluded that the two 
options achieved the same level of IOP reduction, but 
MIGS substantially reduced the use of concomitant medical 
therapy (47% of patients were medication-free at 12 months 
in the MIGS group vs 4% in the SLT group).
In terms of safety, data confirm that risks associated 
with SLT are low: serious adverse events are rare, while 
most of the non-serious adverse events are temporary and 
manageable.71
Minimally Invasive Glaucoma Surgery (MIGS)
Minimally invasive glaucoma surgery (MIGS) has been 
increasingly used over the last 5–10 years; today it is uni-
versally acknowledged by the ophthalmology community as 
a valuable treatment option for glaucoma patients. MIGS 
offers a safer, less invasive means of reducing IOP than 
traditional surgery, with a goal of concomitantly reducing 
utilization of topical agents.84,85 MIGSs are surgical proce-
dures with an ab-interno approach, minimal trauma with 
minimal or no scleral dissection, minimal or no conjunctival 
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manipulation, good safety profile, and rapid recovery.86,87 
However, MIGS comprises a broad range of techniques 
that are significantly different to each other in terms of risk- 
benefit profile. A proposed classification of MIGS is shown 
in Table 1 and is based on approach (ab-interno vs ab- 
externo) and anatomical site of the intervention. As 
a matter of fact, only Schlemm’s canal devices strictly meet 
the definition of MIGS (ie, ab-interno; at the most, limited 
scleral dissection and conjunctival manipulation). Schlemm’s 
canal devices preserve the anatomical integrity of the angle 
structures more than the other options and induce less anato-
mical alterations.88 Furthermore, quality and number of evi-
dences on Schlemm’s canal devices is largely superior to the 
rest of other devices defined as MIGS. For these reasons, the 
present article aims to focus of Schlemm’s canal devices, as 
best representatives of the MIGS class.
Recent reviews and meta-analyses on MIGS were con-
ducted with the aim of assessing the efficacy and safety of 
these techniques, comparatively vs both medical therapy and 
surgery.86,89 In these evaluations, authors conclude that MIGS 
surgery is effective in reducing IOP and the use of glaucoma 
drugs. Also, MIGS showed a good safety profile; IOP spikes 
were the most frequent complications and no cases of infec-
tion or best-corrected visual acuity (BCVA) loss due to glau-
coma were reported. However, the same authors pointed out 
the relatively modest quality of the evidence, which comes 
predominantly from non-comparative trials (only 9 trials out 
of more than 3,000 studies were randomized controlled 
trials). Visualization of the outflow pathways would be help-
ful to drive the choice of the MIGS device.90,91
Among MIGS, iStent (Glaukos Corporation, San 
Clemente, CA, US, hereafter “first-generation TBS”), and 
currently, second-generation TBS have emerged as 
excellent options to achieve sustained IOP reduction with-
out the disadvantages of ocular hypotensive medications. 
The TBS devices are implanted with an ab-interno proce-
dure, designed to optimize the natural physiologic outflow 
of aqueous humor. Beyond efficacy, the greatest advantage 
of these micro-sized devices is they do not preclude filter-
ing surgery that could be required in the future.25,64
The second-generation TBS is a 2-stent system that creates 
2 patent bypasses through the trabecular meshwork. In 2011, 
the second-generation TBS was registered in Europe. To date, 
several studies have shown the safety and efficacy of second 
generation TBS in sustainably reducing IOP and use of med-
ications, either as a combined procedure with concomitant 
cataract,27,92–97 or as a stand-alone procedure (Table 
2).26,98–100
Ophthalmic Drug Delivery Systems
Compared with standard medical therapy, drug delivery sys-
tems have the potential to improve patient adherence, reduce 
side effects, increase efficacy, and ultimately, preserve sight 
of glaucoma patients.101,102 Among these treatments, the 
injectable systems have produced good results in the recent 
past. Injectable systems are passive delivery systems, capable 
of delivering medications to the target tissues for an extended 
period. The injectable systems are typically implanted at the 
site of drug release through a minimally invasive procedure, 
usually in an outpatient setting and they use a polymer deliv-
ery vehicle to prolong delivery up to a few months in the 
surrounding tissue. Recently, Durysta® (bimatoprost implant 
10 mcg), the first intracameral, biodegradable sustained- 
release implant, was approved by FDA to reduce IOP in 
patients with open-angle glaucoma (OAG) or ocular hyper-
tension (OHT).103
Table 1 Classification of MIGS, 
Trabecular Suprachoroidal / Uveoscleral Subconjunctival
Ab-interno 
procedure
● Trabectome® (NeoMedix, Tustin, CA, US)
● First-generation TBS (Glaukos Corp., San 
Clemente, CA, US)
● Second-generation TBS (Glaukos Corp., San 
Clemente, CA, US)
● Hydrus® (Ivantis Inc., Irvine, CA, US)
● Canaloplasty Stegmann Canal® (Ophthalmos 
GmbH, Schaffhausen, Switzerland)
● Cypass® (Alcon, Fort Worth, TX, 
US)a
● iStent Supra® (Glaukos Corp., San 
Clemente, CA, US)b
● Subconjunctival implant (Aquesys 
Implant, Aliso Viejo, CA, US)
● XEN (Allergan, Dublin, Ireland)
Ab-externo 
procedure
- ● Suprachoroidal gold micro shunt 
(SOLX Inc., Waltham, MA, US)
● PreserFlo/InnFocus (Santen, 
Osaka, Japan)
Notes: Data from these studies.84,85. aNo longer available. bNot commercially available. 
Abbreviations: CA, California; MA, Massachusetts; TBS, trabecular micro-bypass stent; US, United States.
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Table 2 Summary of First- and Second-Generation TBS Main Clinical Evidence (Sources Within the Table)
Author (Year) Objective Trial Design Comparators Follow-Up Findings
Samuelson 
(2011)20
Assess the safety and 
efficacy of the first- 
generation TBS in 
combination with 
cataract surgery, in 














endpoint) and 24 
months
● At 1 year, significantly lower IOP (vs baseline) in 
both treatment groups.
● Unmedicated IOP <21 mmHg at 1 year in 72% of 
first-generation TBS treated eyes, vs 50% of con-
trol eyes (P<0.001).
● ≥20% IOP reduction without medication in 66% 
of first-generation TBS treated eyes, vs 48% of 
control eyes (P=0.003).
● Incidence of adverse events similar between 
groups.
Fea (2014)26 Evaluate efficacy 
of second-generation 
TBS in OAG patients 













12 months ● Reduction of ≥20% in 94.7% of eyes with second- 
generation TBS, and in 91.8% of eyes with medical 
therapy, vs baseline unmedicated IOP.
● 17.5% between-group treatment difference in 
favor of second-generation TBS (P=0.02) at the 
≥50% level of IOP reduction.
● IOP ≤18 mmHg in 92.6% of eyes with second- 
generation TBS vs 89.8% of eyes in with medical 
therapy group.




efficacy and safety of 
the second-generation 
TBS + cataract surgery 
in patients with 













47.4 ± 18.46 
months
● IOP decrease of 36.92%, 9.74 ± 3.14 mmHg 
(P<0.001), from baseline.
● Mean number of medications reduced from 1.3 
±0.66 to 0.75±0.79 (P=0.017).
● 45% of patients medication-free by the end of 
follow-up.






TBSs in patients with 
open-angle glaucoma 










18 months ● Postoperative mean IOP: 14.4 mmHg trough 18 
months.
● Mean IOP at month 18: 14.4 mmHg (41% reduction 
from the mean pre-operative unmedicated IOP of 
24.4 mmHg; 27% reduction from the mean pre- 
operative medicated IOP of 19.5 mmHg).





study of second- 
generation TBS with 
phacoemulsification in 














36 months ● Mean postoperative IOP reduction of 37% (14.3 
±1.7 mmHg versus 22.6±6.2 mmHg preopera-
tively), at 36 months.
● Mean medication burden decrease of 68% (0.8 
±0.9 versus 2.5±1.1 medications preoperatively), 
at 36 months.
● IOP reduction of ≥20% in 78% of eyes; 100% of 
eyes reached IOP ≤18 mmHg and 71% reached 
≤15 mmHg.
● From 3 through 36 months, stable mean IOP 
(≤15.0 mmHg) and stable mean number of med-
ications (≤0.9).
(Continued)
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Table 2 (Continued). 
Author (Year) Objective Trial Design Comparators Follow-Up Findings
Samuelson 
(2019) 25
Evaluate safety and 
effectiveness 
of second-generation 
TBS in combination 
with cataract surgery in 











24 months ● Reduction of ≥20% unmedicated DIOP in 75.8% 
of second-generation TBS treated eyes, vs 61.9% 
of control eyes (P=0.005).
● Greater mean reduction in unmedicated DIOP 
from baseline in second-generation TBS treated 
eyes (7.0±4.0 mmHg) than in control eyes (5.4 
±3.7 mmHg; P<0.001).
● 84% of second-generation TBS treated eyes and 
67% of control eyes were not receiving ocular 
hypotensive medication at 23 months.
● 63.2% of treatment eyes vs 50.0% of control eyes 
month 24 medication-free DIOP ≤18 mmHg 
(difference 13.2%; P<0.05).
















36 months ● At 36 months postoperatively, mean IOP reduc-
tion of 42% to 14.6 ± 2.0 mmHg (p<0.0001) and 
87.9% of eyes achieved an IOP reduction of ≥20% 
versus preoperatively.
● 97% of eyes reached IOP ≤18 mmHg (vs 9.1% 
preoperatively; p<0.0001).
● 70.0% of eyes reached IOP ≤15 mmHg (vs 2.3% 
preoperatively; p<0.0001).
● Mean medication burden decrease of 82% to 0.55 
± 0.79 (p<0.0001), and 61% of eyes became 
medication-free.







TBS in conjunction 
with cataract surgery 
for various types of 













12 months ● Mean Month 12 IOP reduction of 23.2% (18.27 
±5.41 mmHg preoperatively to 14.04±2.98 
mmHg).
● 95.8% of eyes achieving Month 12 IOP of ≤18 
mmHg vs 60.6% preoperatively.
● Mean number of medications at 12 months 
decrease of 71.5% (0.47±0.95 vs 1.65±1.28 
preoperatively).
● 76.4% of eyes were on zero medications vs 17.6% 
preoperatively (P<0.001).
● 14.5% of eyes were on ≥2 medications vs 46.7% 
preoperatively (P<0.001).
● 98.2% of eyes maintained or reduced medications 
vs their preoperative regimen.
● Favorable safety profile, no stent-related intrao-
perative complications, and limited postoperative 
adverse events.
(Continued)
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In a Phase 3 study, this system showed ~30% IOP 
reduction in IOP from baseline over a 12-week primary 
efficacy period, meeting the predefined criteria for nonin-
feriority to the study comparator (twice-daily topical 
timolol).104 Moreover, bimatoprost implant improved 
adherence and reduced treatment burden in glaucoma.
Glaucoma Treatment Landscape: 
State of Art in Italy
In Italy, healthcare is supplied for all Italian population 
and is delivered mainly by public providers, with some 
private or private-public entities. Italy’s public healthcare 
system, called Servizio Sanitario Nazionale (SSN), is 
organized by the Ministry of Health and administered on 
a devolved regional basis. It is funded by the government 
through taxation, to provide universal coverage, largely 
free of charge; however, about 30% of the population 
usually subscribes additional private health insurance 
plans.
Ophthalmology departments are part of general hospi-
tals in all the Italian provinces; however, it is not uncom-
mon to find specialized ophthalmic hospitals. More than 
7,000 Italian ophthalmologists are members of the Italian 
Ophthalmological Society (SOI – Società Italiana di 
Oftalmologia-); the total number of ophthalmologists is 
estimated to exceed 8,000.105,106
Treatments that are covered by the public health sys-
tem through small patient co-payment include tests, med-
ications, surgeries during hospitalization, family doctor 
visits and medical assistance provided by paediatricians 
and other specialists, out-patient treatments, and dental 
treatments.
Conventional surgery, MIGS and SLT are predominantly 
performed in public hospital ophthalmology wards, but they 
can also be executed in private clinics (accredited with the 
public sector). The treatment and surgery of glaucoma and 
cataract are classified under the basic national health bene-
fits package, which is supplied to the whole population, 
called LEA (Livelli Essenziali di Assistenza – Essential 
Levels of Assistance). Although MIGSs were introduced 
some time ago, there is still no available codification (or 
reimbursement structure) specifically designed for this type 
of procedure in Italy. At present, Italian surgeons who per-
form MIGS and SLT procedures code them under “other 
glaucoma interventions”; in turn, the reimbursement may be 
insufficient, making hospitals unwilling to adopt and sup-
port this type of surgery.
Today, thanks to the emerging technological innova-
tions developed and optimized during the last decade, 
ophthalmologists have more options to individualize glau-
coma treatment and offer their patients targeted solutions 
to control IOP and disease progression. However, we have 
not seen a significant change in the treatment paradigm yet 
in Italy, or at least we have not seen it on a broad scale. 
Figure 2 provides a schematization of the current treatment 
landscape in Italy, based on our current knowledge. In this 
figure, treatments are ranked by level of use, across the 
different glaucoma stages.
Table 2 (Continued). 
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TBSs vs Prostaglandin 














5 years ● Five-year mean diurnal IOP was 16.51.2 mmHg in 
stent eyes (35.3% reduced vs 25.52.5 mmHg 
preoperatively; P<0.0001) and 16.31.9 mmHg in 
travoprost eyes (35.1% reduced vs 25.14.6 mmHg 
preoperatively; P<0.0001).
● Add-on medication was initiated in 12 stent eyes 
(22.2% of the initial 54-eyes) and 18 travoprost 
eyes (38.3% of the initial 47-eyes).
● 17% (6/35) of stent eyes and 44% (14/32) of 
travoprost eyes needed add-on medication to 
control IOP (P=0.017).
● Treatment success was achieved in 77% (27/35) of 
stent eyes and 53% (17/32) of travoprost eyes 
(P=0.04).
● Both groups exhibited excellent safety.
Abbreviations: CDVA, corrected distance visual acuity; DIOP, diurnal intraocular pressure; IOP, intraocular pressure; OAG, open-angle glaucoma; OHT, ocular 
hypertension; POAG, primary open-angle glaucoma; TBS, trabecular micro-bypass stent.
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In our opinion, four evident issues are emerging from this 
picture: i) despite the availability of new interventions, espe-
cially for mild-to-moderate glaucoma patients, medical ther-
apy remains, de facto, the only treatment adopted in Italy; ii) 
medical therapy is largely applied to all glaucoma stages, and 
the expected trend of reduced use of drugs after surgical 
interventions, observed in clinical trials, is not so evident in 
real practice; iii) SLT and MIGS are used sporadically, their 
use is limited to a few specialized centers in Italy; iv) whereas 
SLT and MIGS are used, they are used quite late in the 
therapeutic sequence, in moderate to advanced glaucoma 
cases that have been exposed to medical therapy for a long 
time and are not controlled any longer.
These four issues can be merged in a single consideration 
reflecting the present landscape in Italy: the majority of Italian 
ophthalmologists adopt a rather conservative approach; this 
implies a slow shift towards a reduction of the use of medical 
therapy in favor of minimally invasive techniques, specifically 
the second-generation TBS, which has been demonstrated to 
safely and sustainably reduce IOP and medications.
Analyzing the reasons for this slow rate of adoption 
and implementing approach modifying actions would be 
of crucial importance for our medical community.
The first issue, perhaps the most important, is the biased 
opinion among ophthalmologists on the value of medical 
therapy. Despite there is no doubt that medical therapy 
remains a valuable option for glaucoma patients, it has been 
“overused” in clinical practice. Long-term IOP control with 
hypotensive drugs in monotherapy at “normal dose ranges” 
is achieved in a relatively small proportion of patients and for 
a limited amount of time.31,107 Consequently, most patients 
are likely to receive more than 2 therapies in the course of 
their treatment pathway. The chronic use of multiple drugs in 
OAG is a relevant clinical issue, which is often underesti-
mated in clinical practice. First, this impacts patients’ QoL 
and their compliance; second, it increases the risk of con-
junctival inflammation, induces damage on the ocular surface 
and compromises the success rate of subsequent 
trabeculectomy.108–111 Therefore, in some patients, this pro-
longed exposure to medical therapy inappropriately post-
pones surgery. Unfortunately, the high burden of 
medication might not be optimized and therefore not the 
best choice for the patients, because glaucomatous damage 
would be irreversible, and because outcomes of surgery 
would be negatively affected by the anatomical changes 
caused by years of medical therapy.111
The second barrier to change would be that perhaps 
fewer investments in time and resources to train ophthal-
mologists have been allocated in Italy, compared to other 
countries, where MIGS is already an established part of 
the treatment paradigm. Of course, every change can gen-
erate concerns; in this specific case, we appreciate that: i) 
switching from medical treatment to new procedural 
approaches is hard to adopt and even harder to commu-
nicate to patients; ii) learning and executing a new proce-
dure is a complex pathway that takes time. These concerns 
are plausible, but they should not be a barrier to adoption. 
Published literature on SLT and MIGS confirms that these 
Figure 2 Overview of current glaucoma treatments in Italy*. -no place in therapy; ○ place in therapy for selected patient subgroups; ● clear place in therapy. *This figure 
schematizes the typical trends of glaucoma treatment in Italy, by disease stage. However, this should not be intended as fully representative of the current situation.
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techniques are relatively “easy-to-learn”.85,112 Evidence 
on second-generation TBS, for instance, suggests that it 
is a very direct and predictable procedure, minimally trau-
matic, with an easy follow-up in both settings, either as 
a standalone procedure or as a combined procedure with 
cataract extraction.113
Patients take eye drops for a few weeks after surgery, 
and no weekly controls are necessary as it is required after 
trabeculectomy because there is no risk of fibrosis and 
recovery is fast. It is easy to reach the Schlemm’s canal 
and place the stents, and you can immediately see the 
success of your surgery.
Certainly, physician education and training are crucial 
for the successful implementation of SLT and MIGS. For 
instance, plenty of literature emphasizes the importance of 
guiding laser, minimally invasive, and traditional inci-
sional surgery with gonioscopy.114–116 The choice of 
gonioscopy settings depends on surgery type and is crucial 
to optimize the procedural success rates. Unfortunately, 
the members of this panel feel that gonioscopy is not 
always performed efficiently by many ophthalmologists. 
Sadly, until these visualization techniques are routinely 
used in Italy, MIGS will be placed later in the treatment 
algorithm, inconsistently with its appropriate place in 
therapy.
The third issue regards the economic sustainability of 
MIGS for hospitals. Several economic evaluations have 
demonstrated that MIGS can be cost-effective for health-
care services, compared to other glaucoma management 
strategies.117–120 Furthermore, there is a clear economic 
rationale to combine cataract extraction and MIGS in one 
single intervention to save procedural costs. However, 
Italian hospitals are not receiving adequate remuneration 
for this combined intervention, to date. As a matter of 
fact, hospitals obtain a remuneration of up to €1,522, 
which is the day-hospital intervention for glaucoma 
(DH 42 “Interventions on intraocular structures except 
for retina, iris and crystalline”),121 barely covering the 
acquisition costs of a MIGS device. In other words, with 
the current remuneration levels, hospitals would not be 
able to afford overall costs (MIGS device, cataract 
intraocular lenses, other procedural costs-room, staffing, 
other equipment, etc.) despite this intervention would be 
cost-effective for the Italian National Health Service 
(NHS). This issue is critical for ophthalmologists and is 
negatively affecting their appetite to learn the new 
techniques.
Place in Therapy Considerations for 
Emerging Glaucoma Treatments in 
Italy
We tried to schematize our suggested place in therapy of 
current and emerging glaucoma treatments using the chart 
showed in Figure 3. Within this concept, identification of 
the optimal therapy by disease stage is based on the 
triangulation of: i) likelihood of the treatment to modify 
ocular surface (thus influencing the choice of future treat-
ments); ii) efficacy of the treatment, intended as the poten-
tial to reduce IOP, iii) optimized use of medical therapy, 
intended as potential to reduce high-doses and/or fre-
quency of combination therapy (≥2 drugs to control IOP).
In summary, we believe that a more individualized 
approach should be adopted when selecting the optimal 
therapy for early-stage patients while filtering surgery 
should remain the preferred option in patients with 
advanced and severe glaucoma, and in selected patients 
with early-onset and rapidly evolving glaucomatous 
damage, despite treatment with medical therapy and less- 
invasive options.
Within this algorithm, the role of medical therapy 
would be significantly revised. Pharmacological treatment 
would be still an option in the early stages of the disease, 
but only in those situations where IOP control can be 
achieved with low-dose monotherapy and other situations 
where other-than medical treatment is contraindicated or is 
not practically feasible.
In other words, our suggested approach is to flexibly 
switch to SLT or MIGS options as early as possible, when 
there is a clear perception that pharmacological treatment 
will hardly be effective.
It should be specified that where multiple options can 
lead to a benefit, patients’ personal preferences should be 
considered. Despite the presence of different techniques, 
there is still a number of patients who would prefer to 
continue medical therapy.122
Medical therapy would remain an important option in 
the post-filtering surgery setting, in those patients who 
have not achieved adequate IOP control and do not have 
any other effective option left.
However, it is important to remark that changes of 
therapeutic approach must always be related to failure/ 
lack of disease control, as any therapeutic modification 
would lead to an increase in the number of visits and 
additional examinations, with consequent increase of 
costs.123
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Back to the early stages of glaucoma, we believe that 
SLT, and second-generation TBS, would be the best options 
to consider in initial glaucoma. With the current data, it is 
hard to set preference between the two techniques. While 
SLT remains the least invasive surgical approach and has 
the advantage of being a repeatable procedure, doubts are 
left about its long-term efficacy.83,124 On the other 
side, second-generation TBS has shown quite robust data 
on sustained IOP reduction with minimal use of medical 
therapy and with excellent safety through 2 years.25,125 
However, a broad utilization in patients with early-stage 
glaucoma might require a large investment, not sustainable 
for the Italian SSN (in Italy, the overall glaucoma popula-
tion amounts to 550 thousand patients).
Given these economic constraints, the most appropriate 
therapeutic positioning of second-generation TBS in initial 
glaucoma would be in patients with additional risk factors 
that could somehow complicate the achievement of opti-
mal and durable IOP.
In this context, patients in need of cataract surgery 
would be ideal candidates for second-generation TBS 
implantation. These patients would undergo surgery any-
way and could benefit from a simultaneous trabecular 
micro-bypass implantation, having the effect of controlling 
IOP without medication in the medium-term time horizon. 
This “all-in-one” intervention has a strong clinical 
rationale and is convenient from an economic and legal 
perspective (hospitals would reduce the number of admis-
sions and patients would be exposed to a single 
intervention).
In moderate glaucoma cases, SLT would remain an 
option for patients who are contraindicated, generally 
unfit, or who are unwilling to undergo surgery, even if 
minimally invasive. For most of the remaining patients, 
MIGS (including second-generation TBS) should be the 
preferred option. The decision on the most suitable tech-
nique, among the possible options, would then depend on 
several factors: ideally, techniques with the lowest level of 
invasiveness, not precluding filtering surgery in the future, 
should be preferred. However, the surgeon should also 
make a decision based on a careful evaluation of proce-
dural complexity, chances of technical success, most sui-
table anatomical site to treat. Even in these patients, there 
would be a strong clinical rationale to consider second- 
generation TBS as one of the most valuable options among 
MIGS devices.
Conclusions
Minimal invasive surgery can be defined as “a technique 
that is safe and is associated with lower postoperative 
patient morbidity compared with a conventional approach 
for the same operation”.126,127 Since its origins (first half 
Figure 3 Suggested place in therapy° of glaucoma treatments in Italy. -no place in therapy; ○ place in therapy for selected patient subgroups; ● clear place in therapy. °Place 
in therapy to be adapted according to available economic resources of the INHS and financial affordability. *Often achieved with combination of medical therapies. **Given 
its better level of safety, second-generation trabecular micro-bypass stent has been differentiated from the other MIGS. MIGS, Minimally invasive glaucoma surgery. 
Abbreviation: INHS, Italian National Health Service.
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of the 20th century), tremendous technological progresses 
have been made, and today, a large proportion of surgical 
procedures in several therapeutic areas (cardiology, oncol-
ogy, gastroenterology, etc.) are performed by minimizing 
invasiveness.
As discussed earlier in this paper, minimally invasive 
surgery of glaucoma has become an important “asset” in 
ophthalmology as well. If yesterday, physicians were quite 
“obliged” to choose between medical therapy and tradi-
tional filtering surgery, today they can make more custo-
mized, personalized decisions optimizing patients’ health 
and quality of life.
In this paper, we aimed to trace a picture of the treat-
ment landscape of glaucoma in Italy, evaluate current use 
and place in therapy of the newer and innovative glaucoma 
treatments, and finally give our perspective on the future 
changes that should be targeted to optimize glaucoma 
therapy. We concluded that the potential of MIGS is 
great, but unfortunately the real impact in the Italian 
clinical setting has been modest so far, and we feel we 
are missing an important opportunity to offer patients the 
best available treatments.
There is a strong rationale for wider use of SLT and MIGS, 
early in the treatment sequence, in patients with mild to 
moderate disease at high risk of suboptimal IOP control with 
medical therapy, or in patients who need high-dose combina-
tion therapy to adequately lower IOP. In this context, 
the second-generation TBS seems one of the best examples 
of the “minimally invasive” concept. This product is safe, 
straightforward to implant, effective in reducing IOP and use 
of medication and is a good candidate to become the standard 
of care in glaucoma patients in need of cataract surgery.
Of course, we understand that any change takes time; 
on top of that, a mindset change like this must be accom-
panied by investments in information and training, and 
improved communication between clinical and surgeon 
ophthalmologists on patient management. Besides, there 
are also funding issues to solve, which are making the use 
of MIGS hardly sustainable by hospitals within the current 
regulatory and remuneration system. Despite all the issues, 
though, we strongly believe that this change is in the best 
interest of patients.
Finally, it is important to acknowledge that this posi-
tion paper should be considered a “dynamic” document, to 
be updated on a regular basis with new findings. 
Importantly, several questions are still open and the 
newly published studies could answer some outstanding 
clinical issues. However, new evidence must always be 
carefully evaluated before accepting new conclusions.
For instance, some doubts on the quality of evidence 
supporting the use of trabecular micro-bypass devices, 
like second-generation TBS, have been raised in a recent 
Cochrane review.128 In contrast with most of the currently 
available studies and technology appraisals, this review 
concluded that the evidence on second-generation TBS 
was not robust enough (effectiveness of the intervention 
has not been clearly demonstrated). However, an in-depth 
analysis of the review suggests that several issues might 
have affected the conclusions: i) the review and meta- 
analyses did not differentiate outcomes between first- 
and second-generation TBS, which are, de facto, two 
different technologies; ii) the review has been conducted 
and published before the publication of the pivotal trial 
of second-generation TBS,25 the most important evidence 
for this product; iii) the clinical outcome that was primar-
ily investigated in the meta-analysis, ie, proportion of 
patients who were drop-free, was not the primary endpoint 
of second-generation TBS trials, which have been 
designed and sampled upon a more traditional, universally 
accepted primary endpoint of proportion of patients with 
≥20% reduction of unmedicated DIOP.25
Also, this conclusion seems to contradict some other 
important observations: i) the level of published evidence 
supporting second-generation TBS is robust; ii) more than 
half a million patients in 40 countries have benefited from 
trabecular micro-bypass therapies;129 iii) important health 
technology assessment agencies in the US and Europe, in 
charge of reimbursement recommendations, have made 
positive recommendations on the use of second- 
generation TBS.130,131
Thus, we strongly believe that years of experience in 
laser technologies and MIGS devices are robust enough to 
include them in the therapeutic algorithm of glaucoma. Of 
course, evidence generation is of crucial importance to 
respond to unanswered questions about comparative evi-
dence among MIGS, or QoL measurement in patients 
undergoing MIGS. But for now, we believe it is more 
important to acknowledge that there is a relevant access 
gap in Italy, and to practically intervene with policies, 
guidelines, information to make these emerging treatments 
available to the Italian patients.
Abbreviations
ACG, angle-closure glaucoma; BCVA, best-corrected 
visual acuity; CDVA, corrected distance visual acuity; 
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DIOP, diurnal intraocular pressure; EGS, European 
Glaucoma Society; IOP, intraocular pressure; MIGS, mini-
mally invasive glaucoma surgery; NHS, National Health 
Service; OAG, open-angle glaucoma; OHT, ocular hyper-
tension; POAG, primary open-angle glaucoma; QoL, qual-
ity of life; SLT, selective laser trabeculoplasty; TBS, 
trabecular micro-bypass stent; US, United States.
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